Articles
| Open Access |
DOI: ASSESSMENT OF THE EFFECTIVENESS OF CARDIOPROTECTIVE DRUGS IN TREATMENT OF CHILDREN WITH DIABETIC CARDIOMYOPATHY
Negmatova Gulzoda Shukhratovna , Assistant, Department of Endocrinology, Samarkand State Medical Institute, Samarkand, Republic of Uzbekistan Togaeva Gulnora Siddiqovna , Assistant, Department of Endocrinology, Samarkand State Medical Institute, Samarkand, Republic of Uzbekistan Davranova Aziza Davranovna , Assistant, Department of Endocrinology, Samarkand State Medical Institute, Samarkand, Republic of Uzbekistan Azimbegova Sitora Nodirovna , Assistant, Department of Endocrinology, Samarkand State Medical Institute, Samarkand, Republic of UzbekistanAbstract
The medical and social significance of type 1 diabetes mellitus (DM) throughout the world is due to early disability and high mortality in patients due to the development of complications, including those from the cardiovascular system. The increase in the life expectancy of patients with diabetes has highlighted the problem of late complications of the disease, the number of which increases with the progression of the disease. The leading cause of death in diabetic patients is cardiovascular accidents. At the same time, it was found that patients with diabetes under the age of 30 years quite often develop coronary heart disease. In addition, the progression of diabetes leads to the development of cardiomyopathy (myocardial dystrophy), myocardiosclerosis, heart failure, life-threatening cardiac arrhythmias, and sudden cardiac death.
Keywords
Diabetes mellitus, cardiomyopathy
References
In children with type 1 diabetes mellitus complicated by diabetic cardiopathy, a negative T wave ECG showed a decrease and flattening of T, depression of the ST segment of low QRS voltage on Echo-KG, a decrease in diastolic rigidity of the myocardium and an increase in LV contractility.
With a decrease in diastolic rigidity of the myocardium and an increase in LV contractility, it is recommended to improve metabolism and systole - diastolic function of the myocardium, stabilize the basic functional indicators of cardiac activity in children and adolescents, the drug Nikovit Cardio in a daily dosage for a period of 30 to 90 days.
To restore myocardial function, the most effective use of drugs that improve metabolism Coenzyme Q10 is a coenzyme of various enzymes involved in myocardial metabolism. Promotes the normalization of lipid metabolism.
REFERENCES
A.M. Makarov, V.V. Berezinskaya et al. "Modern cardiovascular drugs in pediatric cardiology." Grew up. Bulletin of Perinatology and Pediatrics. - 2011. - No. 2. - S. 16-23.
Bodnar P.N "Heart in diabetes mellitus". Probl. Endocrinology. - 2017. - No. 4. - P. 77-81.
Filimonov. M.A. "Preduct and pretarium in the treatment of diabetic myocardial dystrophy." Abstracts. report "Man and Medicine". - M., 2017 .-- S. 212.
Karimova N.A. Narzullaeva D.A. Davranova A.D. Features of phosphorus-calcium metabolism in patients with type 1 diabetes mellitus with diabetic nephropathy. Avicenna 2019. Kemerova. 23-24.
Kasatkina, E. P. Prevention and treatment of late complications of diabetes mellitus in children and adolescents [Text] / E. P. Kasatkina [et al.] // Problems of endocrinology. - 2000. - T. 46, No. 1. - S. 3 - 7.
Narbaev A.N. Togaeva G.S. Khaidarov R.B. Features of the study of multifactorial management of type 2 diabetes. Trends and prospects for the development of science and education in the context of globalization. Pereyaslav-Khmelnitsky. Ukraine. 28 version 2019. Issue 51.323-325.
Article Statistics
Copyright License
Copyright (c) 2022 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.